Banco Santander S.A. grew its position in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 6.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,914 shares of the biopharmaceutical company’s stock after buying an additional 514 shares during the quarter. Banco Santander S.A.’s holdings in Regeneron Pharmaceuticals were worth $3,864,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also recently made changes to their positions in the business. Toroso Investments LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $251,000. Northwestern Mutual Investment Management Company LLC lifted its position in shares of Regeneron Pharmaceuticals by 34.0% in the first quarter. Northwestern Mutual Investment Management Company LLC now owns 4,158 shares of the biopharmaceutical company’s stock worth $2,030,000 after purchasing an additional 1,056 shares in the last quarter. Chase Investment Counsel Corp purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $3,494,000. AGF Investments Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $812,000. Finally, Wrapmanager Inc. lifted its position in shares of Regeneron Pharmaceuticals by 15.4% in the first quarter. Wrapmanager Inc. now owns 1,202 shares of the biopharmaceutical company’s stock worth $587,000 after purchasing an additional 160 shares in the last quarter. Institutional investors own 66.58% of the company’s stock.
In other news, VP Christopher R. Fenimore sold 1,200 shares of the firm’s stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $488.41, for a total value of $586,092.00. Following the sale, the vice president now owns 14,297 shares in the company, valued at $6,982,797.77. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the firm’s stock in a transaction on Monday, March 30th. The stock was sold at an average price of $466.69, for a total transaction of $46,669.00. Following the completion of the sale, the director now owns 29,141 shares in the company, valued at approximately $13,599,813.29. The disclosure for this sale can be found here. In the last 90 days, insiders sold 196,397 shares of company stock worth $109,206,506. 11.84% of the stock is currently owned by corporate insiders.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, May 5th. The biopharmaceutical company reported $6.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.13 by $0.47. The business had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $1.81 billion. Regeneron Pharmaceuticals had a net margin of 28.56% and a return on equity of 24.94%. Regeneron Pharmaceuticals’s quarterly revenue was up 6.8% on a year-over-year basis. During the same quarter last year, the company posted $4.45 earnings per share. On average, analysts forecast that Regeneron Pharmaceuticals Inc will post 23.84 EPS for the current year.
A number of analysts have recently issued reports on REGN shares. Morgan Stanley increased their price target on shares of Regeneron Pharmaceuticals from $409.00 to $555.00 and gave the stock an “equal weight” rating in a research report on Wednesday, May 6th. Cfra increased their price target on shares of Regeneron Pharmaceuticals from $460.00 to $487.00 and gave the stock a “hold” rating in a research report on Wednesday, March 4th. Barclays started coverage on shares of Regeneron Pharmaceuticals in a research report on Thursday, February 27th. They issued an “overweight” rating and a $530.00 price target for the company. Royal Bank of Canada cut their price objective on shares of Regeneron Pharmaceuticals from $533.00 to $524.00 in a research report on Wednesday, May 6th. Finally, BMO Capital Markets raised their price objective on shares of Regeneron Pharmaceuticals from $466.00 to $525.00 and gave the company a “market perform” rating in a research report on Wednesday, May 6th. Fourteen analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. Regeneron Pharmaceuticals presently has an average rating of “Buy” and an average price target of $515.26.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Recommended Story: Yield Curve
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.